As the numbers show, Joby's market cap is more than 1.5 higher compared to Archer's. And yet, Wall Street is expecting Archer to generate more than double Joby's revenue next year. In other words, ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why I rate DERM stock a Buy.

Those sources come from three major retailers (two in the US, all anonymous as ever) and all basically say that RTX 5090 graphics cards are pretty much non-existent in terms of stock. One retailer ...

Getting well into 2025, I'm seeing some passive income stock opportunities that might just have passed under market's radar.

Bharat Electronics (BEL) reported a strong Q3 with 39 per cent revenue growth and a 47.3 per cent increase in net profit. EBITDA surged by 57.5 per cent, and the order book surpassed Rs 70,000 crore.

Tata Motors shares plunged 9 per cent to a 52-week low as Q3 profit fell 22 per cent YoY, missing estimates. JLR performed ...